Guidant Looking For Contak To Regain ICD Market Share Lost To Medtronic
This article was originally published in The Gray Sheet
Executive Summary
Guidant's eroding share in the implantable cardioverter defibrillator market during the first quarter of 2001 can be attributed to increased off-label use of competitor Medtronic's Gem III dual-chamber ICD device to treat patients with congestive heart failure, Guidant officials explained during an earnings teleconference.